Braveheart Bio
Braveheart Bio is a late clinical-stage biotech company developing therapeutics for hypertrophic cardiomyopathy. Its lead asset is BHB-1893.
Secondary Market Price
How Braveheart Bio Measures Up
To help you manage your Braveheart Bio equity, Prospect has run the company through our machine learning model.
Prospect Rating
This rating reflects our belief in this company's potential to grow to that many times its current value in 4 years. For an employee with stock, this rating suggests a potential return on equity, but it also comes with some risk.
Exit Risk
--
Our rating is a reflection of the likelihood of this company achieving a liquidity event for its employees based on the quality of investors, funding stage, founders, and more.
Funding Stage
Series A
A company’s funding stage reflects how established it is, how quickly it is scaling, and the average impact an employee may have when joining.
Secondary Market Price Chart
Create a free account to unlock real-time secondary market prices and future projections of Braveheart Bio's value.
Sign up to Unlock the Latest DataData will be available soon.
Sign up to receive notifications when it is available.
Prospect Projected Future Braveheart Bio Prices
Prospect’s machine learning model has been trained on the same data top-tier investors use to project the likely range of outcomes for Braveheart Bio's equity. Create a free account to view 10th-90th percentile projections over 2, 4, and 6 years.
Powerful tools to earn more from your equity
Company Description
Braveheart Bio is a late clinical-stage biotechnology company that develops novel therapeutics for hypertrophic cardiomyopathy (HCM) and related conditions. The company is currently advancing its lead asset, BHB-1893, through late-stage clinical development. Braveheart Bio was recently launched with the support of several life science investors, including Andreessen Horowitz (a16z Bio + Health), Forbion, OrbiMed, Enavate Sciences, and Frazier Life Sciences. At its launch, the company secured $185 million in a Series A funding round and named Chris Viehbacher as Chair.
Looking forward, Braveheart Bio intends to move its lead asset into late-stage clinical development in 2026, with the goal of establishing a new standard of care for HCM. The company is also actively expanding its team. It was recently announced that CEO and President Travis Murdoch, MD, will present an update on the company's progress and clinical program at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026.
- Andreessen Horowitz
- Forbion
- OrbiMed
- Enavate Sciences
- Frazier Life Sciences
- Co-Founder, CEO Brain Schimpf
- Co-Founder, Travis Murdoch
Peer Group Comparison
Vs Peer Group of >$4B Startups
Frequently Asked Questions
Joining Anduril as an employee is another way to acquire equity, typically through stock options included in compensation packages.
Is Braveheart Bio worth joining?
Joining any startup requires careful consideration of its potential and the value of its equity compensation. Tools like Prospect can help you model the future value of your equity to make a more informed decision.
What should I do with my Braveheart Bio stock?
Deciding what to do with your private company stock involves creating a strategy that aligns with your financial goals and minimizes taxes. Platforms like Prospect offer personalized, tax-optimized equity strategies and scenario modeling to help you determine the best course of action.
Can you sell Braveheart Bio stock?
As a private company, Braveheart Bio stock is not traded on public exchanges, but you may be able to sell shares through secondary markets or during a tender offer. Prospect provides tools and secondary market price information to help you sell your shares at the best price in a tax-optimal way.
How can I find the value of my Braveheart Bio stock?
The value of private stock is typically determined by a 409A valuation, but this may not reflect its market price or future potential. To get a clearer picture, you can use platforms like Prospect, which use predictive models and secondary market data to help forecast your equity's value.
What is Braveheart Bio's equity worth?
The total worth of Braveheart Bio's equity is based on its valuation, which changes with new funding rounds and business performance. To understand what your specific stake might be worth in the future, you can use Prospect's predictive models to project its value under different scenarios.
What is Braveheart Bio's stock ticker symbol?
Braveheart Bio is a private company, so it does not have a stock ticker symbol and is not traded on a public stock exchange. Until an IPO, you can manage your private shares using specialized tools like Prospect to prepare for a future liquidity event.
Can I buy or sell Braveheart Bio stock?
Selling stock in a private company like Braveheart Bio is possible through secondary markets or tender offers, though opportunities can be limited. Platforms like Prospect can help you navigate these sales by providing tender offer tools and tax optimization strategies.
What is the criteria to buy or invest in Braveheart Bio stock?
Investing in a private company like Braveheart Bio is typically limited to institutional investors, accredited investors, or employees who receive equity as part of their compensation. If you are an employee with equity, you can use tools from Prospect to manage and maximize the value of your holdings.
